RECURSION PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $74.7 | $58.8 | $44.6 | $39.8 | $10.2 |
| Operating income | -$648.1 | -$479.0 | -$350.1 | -$245.7 | -$182.8 |
| Net income | -$644.8 | -$463.7 | -$328.1 | -$239.5 | -$186.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$378.3 | -$372.9 | -$299.7 | -$120.6 | -$198.4 |
Shares outstanding 540.6M · Free float 93.2%
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.